Tumefactive Demyelinating Lesions in a Patient with Multiple Sclerosis Developed two Days after the Injection of Rituximab.BACKGROUND
 Rituximab has been increasingly prescribed in the treatment of multiple sclerosis (MS) over recent years.  This study is a case report of a young MS patient who suffered from tumefactive lesions following the injection of rituximab.


 The patient was an 18-year-old man with MS who developed double vision, imbalance, and quadriparesis symptoms followed by a decrease in his consciousness two days after administration of rituximab.  Rituximab should be considered as a potential cause of tumefactive demyelinating lesions in patients with MS.
rituximab